Wells Fargo raised the firm’s price target on Medtronic (MDT) to $114 from $100 and keeps an Overweight rating on the shares. The firm notes Q2 organic growth of 5.5% exceeded Street, while EPS beat even with the increased opex spend. Medtronic continues to expect a top-line acceleration into the second half of the year and beyond, Wells adds.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Cautious Hold Rating on Medtronic Amid Mixed Segment Performance and Uncertain Growth Prospects
- Medtronic price target raised to $111 from $98 at Bernstein
- Medtronic’s Strategic Growth and Cautious Optimism Amid Fiscal Gains and Investment Needs
- Medtronic Reports Strong Q2 2026 Financial Results
- Medtronic upgraded to Neutral from Sell at Goldman Sachs